Olaparib with high-dose chemo for hard-to-treat germ cell tumors
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding a drug called olaparib (a PARP inhibitor) to high-dose chemotherapy can help treat germ cell tumors that have come back or not responded to previous treatment. The goal is to improve the chances of the chemotherapy working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 60 years old.
- Your germ cell tumor must have come back after treatment, not responded to the last treatment, or started in a part of the body outside the testicles or ovaries.
- You need to have already had enough stem cells collected (for a stem cell transplant) — at least 5 million cells per kilogram of body weight.
- Your blood counts, kidney function, and liver function must be within the ranges the study requires.
- If you are a woman who could become pregnant, or a man with a partner who could, you must use effective birth control during the study.
- You must not have had major surgery within the past 30 days or radiation therapy within the past 21 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
Hear when a new Germ Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.